Fatality rates in candida infections are between 30 and 40 percent. Until the advent of lipid-based products, conventional amphotericin B was generally considered to be the treatment of choice to combat these infections. However, its propensity to cause kidney toxicity has severely limited its dosage, a result that many believe limits its efficacy. Marketing applications have been filed and are being reviewed in a number of other countries. The Liposome Company is a broad-based biopharmaceutical company developing and marketing products based on its knowledge of lipids and liposomes.
Research programs are underway in cancer, inflammation and gene therapy delivery.
Consulting Group Inc. All rights reserved. Please contact us with any comments, problems or bugs. Consulting Group Inc. All rights reserved.